User:S4188552: Difference between revisions
Line 33: | Line 33: | ||
==Ecology== | ==Ecology== | ||
V. parvula is a strict anaerobe that ideally grows at 37C and a pH range of 6.5 to 8.0, as such humans present as the ideal host. It is most commonly found within the human oral cavity and gastrointestinal tract, although it may also be found within the genitourinary and respiratory tracks [5, 7]. Owing to V. parvula’s inability to directly adhere to host surfaces it has no direct microbe to host interactions, rather it relies upon interactions with other microbes within the same biological niche [5]. Specifically it is commonly a key early colonizer in early oral biofilm formation and facilitates the colonizing of middle and late phase pathogenic colonizers responsible for direct host/microbe interactions [6]. | |||
==Pathology== | ==Pathology== |
Revision as of 11:02, 23 September 2016
Aimee Davidson Bench E 23 Sept 2016 [1]
Classification
Higher order taxa
Bacteria - Firmicutes - Negativicutes - Selenomonadales - Veillonellaceae - Veillonella [3]
Species
Species name: Veillonella parvula (subspecies parvula) [3]
Type strain: ATCC 10790 = CCUG 5123 = DSM 2008 = JCM 12972 = NCTC 11810 [3]
Description and significance
Veillonella parvula is one of thirteen species of the Veillonella genus and one of only six of these species to be found within the human oral cavity [6]. V.parvula was originally dubbed Staphylococcus parvulus, by Veillon and Zuber in 1898, who first isolated and cultured the bacteria from an infected human appendix [11]. It was subsequently further described and renamed Veillonella parvula in 1933 by Prevot [11]. V. parvula is a small gram-negative cocci, typically between 0.3-0.5 microns in diameter -which can be identitified by its characteristic pair grouping and distinctive red fluorescence under UV light and certain growth conditions [4]. As mentioned previously it is commonly found within the human oral cavity, specifically on the tongue, buccal mucosa and in the saliva, however it can also be found within the human gastrointestinal, genitourinary and respiratory tracks [5, 7]. Initially, V. parvula was thought to be non-pathogenic accounting for up to 98 % of cultivable Veillonella species in healthy human oral cavities [5]. However, it is now known that while it is typically not directly pathogenic it regularly coaggregates with other pathogenic species, such as streptococcus and is a key early colonizer for the formation of oral biofilms [6].
Genome structure
V. parvula exhibits a circular 2.13 Mb (2,132,142 bp) genome, of which 88.46 % is DNA encoding, and was the first member of the Veillonella genus to have its complete genome sequenced. Its 1920 genes include: 1859 protein-encoding genes, 61 RNA specific genes and 15 pseudogenes, with an overall GC content of 38.63%. The majority of these genes are predicted to have either an unknown (385 genes) or general function (177 genes).- those genes with a predicted function are predominately involved with: translation, ribosomal structure, cell wall or membrane biogenesis, energy production and conversion, amino acid, coenzyme and inorganic transport and metabolism [5]
Cell structure and metabolism
Verkley et al established that 98 % of the phosphoglycerides that comprise V. parvula's cell membrane are either serine or ethanolamine based. These phosphoglycerides typically exist in single bonded carbon chains consisting of between 11 to 19 carbons, although chains containing 15,17,18 or 19 carbons atoms may also contain one double carbon bond [12]. Additionally, many of these phosphoglycerides exist in a plasmogen form which is thought to have an important role in the regulation of the cell's membrane fluidity [12, 8]. The peptidoglycan cell wall of V. parvula consists of: glutamic acid in the D configuration; diaminopimelic acid in the meso configuration; and alpha-linked cadaverine and putrescine to glutamic acid [5]. V. parvula lack flagella, spores and capsules and the ability to adhere to surfaces [6, 5]. It overcomes this lack of surface adhesion by adhering to specific surface structures on other bacterial species through lectin-carbohydrate mediated interactions [5]. V. parvula is unable to utilise carbohydrates, such as glucose, or amino acids in its energy production but rather utilises the metabolic end products of closely associated bacteria within the environment, particularly lactic acid producing species [5, 11]. That is,it is able to metabolise lactate, pyruvate, malate and fumarate to produce propionate, acetic acid, carbon dioxide (CO2) and hydrogen [5]. In addition, Ng and Hamilton established that V. parvula produces greater quantities of CO2 and propionate, which is explicitly shown in the following general equation of lactate metabolism:
Ecology
V. parvula is a strict anaerobe that ideally grows at 37C and a pH range of 6.5 to 8.0, as such humans present as the ideal host. It is most commonly found within the human oral cavity and gastrointestinal tract, although it may also be found within the genitourinary and respiratory tracks [5, 7]. Owing to V. parvula’s inability to directly adhere to host surfaces it has no direct microbe to host interactions, rather it relies upon interactions with other microbes within the same biological niche [5]. Specifically it is commonly a key early colonizer in early oral biofilm formation and facilitates the colonizing of middle and late phase pathogenic colonizers responsible for direct host/microbe interactions [6].
Pathology
V. parvula has a well established association with human oral diseases, in particular demonstrating a strong association with severe early childhood carries and intraradicular infections [5],[6]. Recent research has also revealed that V. parvula is the predominant Veillonella species within dentine biofilms[10]. Although V. parvula generally presents as a commensal or non-pathogenic resident in the bacterial communities of the oropharynx and the gastrointestinal, genitourinary and respiratory tracks [7], it has rarely been associated with a number of serious and life-threatening infections. These infections include: osteomyeltitis, spondylodiscitis, discitis, meningitis and sinus infections [7], [8]. It has demonstrated resistance against a wide range of antibiotics including: tetracycline, erythromycin, gentamicin, karamycin, chloramphenicol and lincomycin. Although importantly at the time of its genome sequencing in 2010 it was still susceptible to penicillin, cephalotin and clindamycin [5].
Application to biotechnology
Bioengineering, biotechnologically relevant enzyme/compound production, drug targets,…
Current research
Summarise some of the most recent discoveries regarding this species.
References
References examples
3. List of prokaryotic names with standing in nomenclature
- ↑ MICR3004
This page is written by Aimee Davidson for the MICR3004 course, Semester 2, 2016